Cargando…

Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey

BACKGROUND: Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their...

Descripción completa

Detalles Bibliográficos
Autores principales: Guiraud, Marlene, Bouroubi, Athmane, Beauchamp, Roxane, Bocquet, Arnaud, Grégoire, Jean-Marc, Rauly-Lestienne, Isabelle, Blanco, Ignacio, Wolkenstein, Pierre, Schmitt, Anne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894276/
https://www.ncbi.nlm.nih.gov/pubmed/31801570
http://dx.doi.org/10.1186/s13023-019-1265-4
_version_ 1783476358671761408
author Guiraud, Marlene
Bouroubi, Athmane
Beauchamp, Roxane
Bocquet, Arnaud
Grégoire, Jean-Marc
Rauly-Lestienne, Isabelle
Blanco, Ignacio
Wolkenstein, Pierre
Schmitt, Anne-Marie
author_facet Guiraud, Marlene
Bouroubi, Athmane
Beauchamp, Roxane
Bocquet, Arnaud
Grégoire, Jean-Marc
Rauly-Lestienne, Isabelle
Blanco, Ignacio
Wolkenstein, Pierre
Schmitt, Anne-Marie
author_sort Guiraud, Marlene
collection PubMed
description BACKGROUND: Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their satisfaction and feelings about cNF current management (only laser and surgery are currently available), and to highlight their expectations of new therapeutic modalities. RESULTS: One hundred seventy patients from 4 European countries took part in the study, 65% (n = 110) were women and mean age was 39 years old. 96% (n = 164) of respondents have cNF on visible parts of the body and the survey confirmed that total number of cNF and visibility increase with age. Patients reported that cNF mainly impacts everyday mood, general daily life and social life. The visibility of cNF had a higher impact than their number. 92% (n = 156) of patients have a regular and multidisciplinary medical follow-up. The dermatologist is one of the most consulted healthcare professionals. 76% (n = 130) of respondents have treated their cNF: 65% (n = 111) had surgery and 38% (n = 64) had multiple laser sessions. Frequency of operations and regrowth of cNF were the two most unsatisfactory aspects with both treatments for patients. Indeed, after removal, new cNF appear in more than 75% (n = 128) of cases. As a future treatment, patients expected a topical (30%, n = 51) or oral medication (29%, n = 50). Around 2 out of 3 patients would agree to take it at least once a day or more for life but they would like a well-tolerated treatment. According to patients, the most important effectiveness criteria of a new treatment are to block cNF growth and reduce their number. 70% (n = 119) of patients would consider a future treatment moderately effective to very effective if it could clear 30% of cNF. CONCLUSIONS: This first cNF European patient community survey confirmed that the visible stigma and unaesthetic aspect of cNF have an important impact on patients’ quality of life. The survey highlighted that patients were not entirely satisfied with the actual surgery and laser treatments and revealed their clear and realistic expectations for future treatment of cNF.
format Online
Article
Text
id pubmed-6894276
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68942762019-12-11 Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey Guiraud, Marlene Bouroubi, Athmane Beauchamp, Roxane Bocquet, Arnaud Grégoire, Jean-Marc Rauly-Lestienne, Isabelle Blanco, Ignacio Wolkenstein, Pierre Schmitt, Anne-Marie Orphanet J Rare Dis Research BACKGROUND: Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their satisfaction and feelings about cNF current management (only laser and surgery are currently available), and to highlight their expectations of new therapeutic modalities. RESULTS: One hundred seventy patients from 4 European countries took part in the study, 65% (n = 110) were women and mean age was 39 years old. 96% (n = 164) of respondents have cNF on visible parts of the body and the survey confirmed that total number of cNF and visibility increase with age. Patients reported that cNF mainly impacts everyday mood, general daily life and social life. The visibility of cNF had a higher impact than their number. 92% (n = 156) of patients have a regular and multidisciplinary medical follow-up. The dermatologist is one of the most consulted healthcare professionals. 76% (n = 130) of respondents have treated their cNF: 65% (n = 111) had surgery and 38% (n = 64) had multiple laser sessions. Frequency of operations and regrowth of cNF were the two most unsatisfactory aspects with both treatments for patients. Indeed, after removal, new cNF appear in more than 75% (n = 128) of cases. As a future treatment, patients expected a topical (30%, n = 51) or oral medication (29%, n = 50). Around 2 out of 3 patients would agree to take it at least once a day or more for life but they would like a well-tolerated treatment. According to patients, the most important effectiveness criteria of a new treatment are to block cNF growth and reduce their number. 70% (n = 119) of patients would consider a future treatment moderately effective to very effective if it could clear 30% of cNF. CONCLUSIONS: This first cNF European patient community survey confirmed that the visible stigma and unaesthetic aspect of cNF have an important impact on patients’ quality of life. The survey highlighted that patients were not entirely satisfied with the actual surgery and laser treatments and revealed their clear and realistic expectations for future treatment of cNF. BioMed Central 2019-12-04 /pmc/articles/PMC6894276/ /pubmed/31801570 http://dx.doi.org/10.1186/s13023-019-1265-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Guiraud, Marlene
Bouroubi, Athmane
Beauchamp, Roxane
Bocquet, Arnaud
Grégoire, Jean-Marc
Rauly-Lestienne, Isabelle
Blanco, Ignacio
Wolkenstein, Pierre
Schmitt, Anne-Marie
Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title_full Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title_fullStr Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title_full_unstemmed Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title_short Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
title_sort cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online european patient community survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894276/
https://www.ncbi.nlm.nih.gov/pubmed/31801570
http://dx.doi.org/10.1186/s13023-019-1265-4
work_keys_str_mv AT guiraudmarlene cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT bouroubiathmane cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT beauchamproxane cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT bocquetarnaud cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT gregoirejeanmarc cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT raulylestienneisabelle cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT blancoignacio cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT wolkensteinpierre cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey
AT schmittannemarie cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey